Feds Urge Cuts in Use of Anti-Psychotic Drugs for Seniors
Federal regulators are turning up the heat to reduce the alarming quantity of dangerous, costly, and unnecessary anti-psychotic drugs prescribed to seniors to quell dementia-related anxiety—not just in nursing homes, but in hospitals too.
Nearly nine out of 10 times in which these drugs, such as risperidone (Risperdal), are given to Medicare beneficiaries, they are for uses that regulators have not approved, an Office of Inspector General's report said last May.
And it's not just risperidone. The U.S. Food and Drug Administration has approved eight drugs, Aripiprazole, Clozapine, Olanzapine, Olanzapine/Fluoxetine, Paliperidone, Quetiapine, Risperidone, and Ziprasidone, to treat schizophrenia and acute manic and mixed episodes associated with bipolar disorder, but specifically says the drugs are not approved to treat dementia-related agitation or psychosis in seniors.
Dangers include increased chance of death, life-threatening nervous system problems, movement disorders, high blood sugar and diabetes, and low blood pressure. Other risks include increased rates of pneumonia and pressure ulcers.
- 12 Hires to Keep Your Hospital Out of Trouble
- Ratcheting Up Patient Experience Has a Downside
- Meaningful Use Payment Adjustments Begin
- 'Mega Boards' Could be Rural Healthcare Disruptor
- HL20: Lee Aase—Who's Behind @MayoClinic
- 1 in 5 Eligible Hospitals Penalized for HACs
- Taming Time and Moving Healthcare Data
- A Christmas Wish List for US Healthcare
- HL20: Sam Foote, MD—The Courage to Speak Up
- HL20: Derek Angus, MD—An Intense Focus on Care